DRKS00025847招募中不适用
Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities) - MTB-FR
niversitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation0 个研究点目标入组 1,000 人开始时间: 2021年7月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)
- •2. there are no curative or inadequate treatment options available
- •3. the expected life expectancy of the patient should be above 6 months
- •4. sufficient tumor tissue available for a backup sample that can be used for future diagnostic studies
排除标准
- •1. lack of capacity to give consent or lack of informed consent for the registry study
- •2. lack of a suitable tumor biopsy or too little tissue available for a reserve sample
研究者
相似试验
招募中
不适用
Molecular Tumor Board - A Registry of the East German Hematology and Oncology Study Group.hematologic or oncologic diseasesDRKS00032977Martin-Luther-Universität Halle-Wittenberg250
招募中
不适用
Prospective observational study molecular tumor board of the Comprehensive Cancer Center Mainfranken of the University Hospital of WürzburgC00-C97Malignant neoplasmsDRKS00029051niversitätsklinikum Würzburg998
招募中
2 期
CAncer TReatment INformed by the Molecular Tumor Board At DartmouthCancerNCT05405413Dartmouth-Hitchcock Medical Center192
进行中（未招募）
1 期
Tumor profilingPatients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected.EUCTR2014-005341-44-ATMedical University of Graz64
招募中
不适用
Registry of the molekularen tumor boards of the University Cancer Centers Schleswig-Holstein (short title: „UCCSH-MTB-registry)solid tumors and hematologic neoplasiaC00-C97Malignant neoplasmsDRKS00028806niversitätsklinikum Schleswig-Holstein, Lübeck Klinik für Hämatologie und Onkologie1,000